newsfilter
← Latest News
GlobeNewswire·

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

  • Chemomab Therapeutics CEO Adi Mor, PhD, will present at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, at the Sofitel Hotel in New York City.
  • The invitation-only summit includes panels, presentations, & 1-on-1 investor meetings focused on the rare disease sector.
  • Dr. Mor's presentation is scheduled from 2:15 PM to 2:45 PM EST & he will be available for individual meetings with registered attendees.
  • Chemomab is a clinical-stage biotech developing nebokitug, a first-in-class dual-activity monoclonal antibody targeting the protein CCL24 for fibro-inflammatory diseases.
  • Nebokitug has demonstrated disease-modifying potential & a favorable safety profile across five clinical trials.
  • Positive Phase 2 SPRING trial data in primary sclerosing cholangitis (PSC) has led the company to prepare for a potential Phase 3 pivotal trial with a streamlined regulatory pathway.
  • Nebokitug holds FDA & EMA Orphan Drug designations & FDA Fast Track designation for PSC treatment.
  • The company maintains an open U.S. IND for its nebokitug program targeting systemic sclerosis.
  • Interested parties must contact an Oppenheimer representative to register for the summit & schedule a meeting with Dr. Mor.